Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability (Q34869256)

5 August 2017

1 reference

title

Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability (English)

1 reference

5 August 2017

0 references

David Taylor

2

0 references

author name string

Delia Bishara

series ordinal

1

1 reference

5 August 2017

1 January 2008

1 reference

5 August 2017

1 reference

5 August 2017

68

1 reference

5 August 2017

2269-2292

1 reference

5 August 2017

16

1 reference

https://scigraph.springernature.com/pub.10.2165/0003495-200868160-00002

5 August 2017

0 references

cites work

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F0003495-200868160-00002

Pharmacological studies on a new benzamide derivative, YM-09151-2, with potential neuroleptic properties

21 January 2018

1 reference

12 December 2020

Pharmacological actions of the atypical antipsychotic drug clozapine: a review

1 reference

12 December 2020

Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding

1 reference

12 December 2020

A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia

1 reference

12 December 2020

Health resource utilization associated with switching to risperidone long-acting injection

1 reference

12 December 2020

Acute dystonia during fixed-dose neuroleptic treatment

1 reference

12 December 2020

Dopamine D4-like binding sites labeled by [3H]nemonapride include substantial serotonin 5-HT2A receptors in primate cerebral cortex.

1 reference

12 December 2020

Limbic selectivity of clozapine.

1 reference

12 December 2020

The global costs of schizophrenia

1 reference

12 December 2020

Clozapine, single photon emission tomography, and the D2 dopamine receptor blockade hypothesis of schizophrenia

1 reference

12 December 2020

Plasma level monitoring of antipsychotic drugs. Clinical utility

1 reference

12 December 2020

Characteristics and risk factors of acute dystonia in schizophrenic patients treated with nemonapride, a selective dopamine antagonist.

1 reference

12 December 2020

Evidence for a role of haloperidol-sensitive sigma-'opiate' receptors in the motor effects of antipsychotic drugs

1 reference

12 December 2020

Metabolism and bioactivation of clozapine by human liver in vitro

1 reference

12 December 2020

Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia

1 reference

12 December 2020

Serotonin-dopamine interaction and its relevance to schizophrenia

1 reference

12 December 2020

Quetiapine: an effective antipsychotic in first-episode schizophrenia despite only transiently high dopamine-2 receptor blockade.

1 reference

12 December 2020

Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles

1 reference

12 December 2020

Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action

1 reference

12 December 2020

Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis

1 reference

12 December 2020

Risk of weight gain associated with antipsychotic treatment: results from the Canadian National Outcomes Measurement Study in Schizophrenia

1 reference

12 December 2020

Atypical antipsychotics: mechanism of action.

1 reference

12 December 2020

Antipsychotics and diabetes: review of non-prospective data.

1 reference

12 December 2020

Biochemical evidence that the atypical antipsychotic drugs clozapine and risperidone block 5-HT(2C) receptors in vivo

1 reference

12 December 2020

A review of the effect of atypical antipsychotics on weight

1 reference

12 December 2020

5-HT1A receptor agonist properties of the antipsychotic, nemonapride: comparison with bromerguride and clozapine.

1 reference

12 December 2020

Dopamine D2 receptor occupancy predicts catalepsy and the suppression of conditioned avoidance response behavior in rats.

1 reference

12 December 2020

Atypical antipsychotics and weight gain--a systematic review

1 reference

12 December 2020

Dose-response relationships of perphenazine in the treatment of acute psychoses

1 reference

12 December 2020

Clozapine and dopamine D(2) blockade

1 reference

12 December 2020

Effects of reserpine treatment on the dopamine receptor binding of [3H/11C]nemonapride in the mouse and rat brain

1 reference

12 December 2020

Dopamine partial agonists: a new class of antipsychotic

1 reference

12 December 2020

A Double-Blind, Randomized, Placebo-Controlled Trial of Olanzapine in the Prevention of Psychotic Relapse

1 reference

12 December 2020

Long-term therapeutic drug monitoring of clozapine and metabolites in psychiatric in- and outpatients

1 reference

12 December 2020

Dopamine D2 receptor occupancy in vivo by the novel atypical antipsychotic olanzapine--a 123I IBZM single photon emission tomography (SPET) study.

1 reference

12 December 2020

Clozapine and N-desmethylclozapine are potent 5-HT1C receptor antagonists.

1 reference

12 December 2020

Risperidone in the treatment of schizophrenia

1 reference

12 December 2020

Dopamine D(2) receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects

1 reference

12 December 2020

Pharmacological and molecular targets in the search for novel antipsychotics

1 reference

12 December 2020

[3H]YM-09151-2 (nemonapride), a potent radioligand for both sigma 1 and sigma 2 receptor subtypes.

1 reference

12 December 2020

Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist

1 reference

12 December 2020

Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group

1 reference

12 December 2020

Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial

1 reference

12 December 2020

Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial.

1 reference

12 December 2020

Dopamine D4 receptors elevated in schizophrenia

1 reference

12 December 2020

In vivo binding of [11C]nemonapride to sigma receptors in the cortex and cerebellum

1 reference

12 December 2020

Clozapine-induced agranulocytosis. Incidence and risk factors in the United States

1 reference

12 December 2020

Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence

1 reference

12 December 2020

Alpha2C-adrenoceptor overexpression disrupts execution of spatial and non-spatial search patterns.

1 reference

12 December 2020

The semistructured BPRS interview and rating guide

1 reference

12 December 2020

Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study

1 reference

12 December 2020

The Clinical Global Impression-Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia

1 reference

12 December 2020

Exploring the pharmacology of the pro-convulsant effects of alpha 2-adrenoceptor antagonists in mice

1 reference

12 December 2020

Prospective 6-month follow-up of patients prescribed risperidone long-acting injection: factors predicting favourable outcome

1 reference

12 December 2020

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

1 reference

12 December 2020

Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder

1 reference

12 December 2020

Reversal of antipsychotic-induced working memory deficits by short-term dopamine D1 receptor stimulation

1 reference

12 December 2020

Regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat.

1 reference

12 December 2020

Antipsychotic drug doses and neuroleptic/dopamine receptors

1 reference

12 December 2020

Clinical outcome and plasma levels of clozapine and norclozapine in drug-resistant schizophrenic patients

1 reference

12 December 2020

A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients

1 reference

12 December 2020

5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation.

1 reference

12 December 2020

Alpha-adrenoceptor modulation hypothesis of antipsychotic atypicality

1 reference

12 December 2020

In vitro receptor binding and in vivo receptor occupancy in rat and guinea pig brain: risperidone compared with antipsychotics hitherto used.

1 reference

12 December 2020

Evaluation of N-desmethylclozapine as a potential antipsychotic--preclinical studies

1 reference

12 December 2020

Predictors of acute dystonia in first-episode psychotic patients.

1 reference

12 December 2020

Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors

1 reference

12 December 2020

Neuroleptic properties of cis-N-(1-benzyl-2-methylpyrrolidin-3-yl)-5-chloro-2-methoxy-4-methylaminobenzamide (YM-09151-2) with selective antidopaminergic activity

1 reference

12 December 2020

Neuroleptic-induced hyperprolactinemia

1 reference

12 December 2020

Safety profile of iloperidone: a pooled analysis of 6-week acute-phase pivotal trials

1 reference

12 December 2020

Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity.

1 reference

12 December 2020

Plasma concentrations of risperidone and 9-hydroxyrisperidone: effect of comedication with carbamazepine or valproate

1 reference

12 December 2020

Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia

1 reference

12 December 2020

Extended radioligand binding profile of iloperidone: a broad spectrum dopamine/serotonin/norepinephrine receptor antagonist for the management of psychotic disorders

1 reference

12 December 2020

Asenapine: a novel psychopharmacologic agent with a unique human receptor signature

1 reference

12 December 2020

Barriers to employment for people with schizophrenia

1 reference

12 December 2020

Radioreceptor binding profile of the atypical antipsychotic olanzapine.

1 reference

12 December 2020

Asenapine, a novel psychopharmacologic agent: preclinical evidence for clinical effects in schizophrenia.

1 reference

12 December 2020

Antipsychotic-induced weight gain: a comprehensive research synthesis

1 reference

12 December 2020

All-cause treatment discontinuation in schizophrenia during treatment with olanzapine relative to other antipsychotics: an integrated analysis

1 reference

12 December 2020

Associations between side effects of nemonapride and plasma concentrations of the drug and prolactin

1 reference

12 December 2020

The pipeline and future of drug development in schizophrenia.

1 reference

12 December 2020

Therapeutic spectrum of nemonapride and its relationship with plasma concentrations of the drug and prolactin

1 reference

12 December 2020

D2 receptor occupancy of olanzapine pamoate depot using positron emission tomography: an open-label study in patients with schizophrenia.

1 reference

12 December 2020

Increased dopamine transmission in schizophrenia: relationship to illness phases

1 reference

12 December 2020

A point mutation (D79N) of the alpha2A adrenergic receptor abolishes the antiepileptogenic action of endogenous norepinephrine

1 reference

12 December 2020

EFFECT OF CHLORPROMAZINE OR HALOPERIDOL ON FORMATION OF 3METHOXYTYRAMINE AND NORMETANEPHRINE IN MOUSE BRAIN.

1 reference

12 December 2020

N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl- d -aspartate receptor activity

1 reference

12 December 2020

Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial

1 reference

12 December 2020

Haloperidol plasma levels and clinical response: a therapeutic window relationship

1 reference

12 December 2020

Paliperidone: quo vadis?

1 reference

12 December 2020

Alpha2C-adrenoceptor-overexpressing mice are impaired in executing nonspatial and spatial escape strategies.

1 reference

12 December 2020

Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management

1 reference

12 December 2020

Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT).

1 reference

12 December 2020

A rating scale for extrapyramidal side effects

1 reference

12 December 2020

Contributions of five human cytochrome P450 isoforms to the N-demethylation of clozapine in vitro at low and high concentrations

1 reference

12 December 2020

The Barnes Akathisia Rating Scale--revisited

1 reference

12 December 2020

Comparison of [3H]YM-09151-2 with [3H]spiperone and [3H]raclopride for dopamine d-2 receptor binding to rat striatum

1 reference

12 December 2020

Iloperidone binding to human and rat dopamine and 5-HT receptors

1 reference

12 December 2020

The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine

1 reference

12 December 2020

Is regionally selective D2/D3 dopamine occupancy sufficient for atypical antipsychotic effect? an in vivo quantitative [123I]epidepride SPET study of amisulpride-treated patients

1 reference

12 December 2020

The positive and negative syndrome scale (PANSS) for schizophrenia

1 reference

12 December 2020

The role of serotonin in antipsychotic drug action

1 reference

12 December 2020

The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor

1 reference

12 December 2020

Intra- and interindividual variations in steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients treated chronically with various doses of risperidone

1 reference

12 December 2020

10.2165/0003495-200868160-00002

Identifiers

DOI

1 reference

PubMed ID

18973393

Dimensions Publication ID

5 August 2017

0 references

1 reference

PubMed ID

18973393